Avicanna aims to establish itself as a leader in the global medical cannabis industry through its product discovery and development processes, intellectual property portfolio, strategic relationships, and cultivation infrastructure. Avicanna believes that its two main business segments, namely research and development or “R&D” and cultivation, strategically position it to be a front runner in the development, manufacturing and commercialization of plant-derived cannabinoid-based products and Extracts throughout North America, Latin America, Europe and Asia. It intends to capitalize on the nexus between both business segments where the intellectual property gained from its R&D efforts is used to inform and improve the products of its cultivation and extraction activities and the raw materials from its cultivation and extraction efforts can be used to further its R&D activities; and Avicanna anticipates, in both cases, to benefit from a reduced cost from what would be incurred through purchasing such intellectual property or raw materials, as the case may be, from third parties. Avicanna is growing its network of strategic relationships with institutions they believe to be best-in-class and market leading, located around the world to assist with the achievement of its business objectives, including large-scale, environmentally sustainable cultivation, scientific R&D, and manufacturing and distribution.
Aras Azadian – CEO : Aras brings extensive senior management experience in the biotechnology and financial sectors including his involvement in several successful start-up companies. In addition to his international experience in corporate development, his diverse roles include his previous position as the president of an investment corporation in the cannabis space and former Chief Operating Officer of an oncology company. Aras holds a Bachelor of Economics degree from York University in Toronto, and an International Masters in Management degree from EADA Business School in Barcelona, Spain.